RLYB - צמיחת מכירות משנה לשנה (TTM) rallybio.com

The annual revenue growth dynamics over a rolling period for Rallybio Corporation (RLYB) are comparable to the base value of its patents and funding. The current value of -35.10 characterizes this valuation parameter. Growth is supported by the development of antibodies for neonatal health and the prevention of fetal pathologies. Process stability is ensured by the air freight of bioccomponents, which eliminates supply chain disruptions during drug development.
Rallybio Corp. (RLYB) - פילוחי מדדים ודוחות פיננסיים

This indicator captures the percentage change in revenue over a rolling 12-month period, reflecting the pace of business expansion. Professionals utilize the current year-over-year revenue growth rate (TTM) to verify the scalability of commercial operations. A steady upward trend confirms organic growth, whereas sharp peaks signal the risk of overpayment. For Rallybio Corporation (RLYB), this metric is secondary to clinical success. The company's valuation is driven by trial results for rare pathologies, regardless of macroeconomic conditions.